MedTrace Logo

Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin

NCT03889496 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-07-12

No results posted yet for this study

Summary

The main goal is to study the correlation of pancreatic uptake of In-111-DTPA-exendin-4 (measured by ex vivo counting) with the beta cell mass determined in the pancreatic specimens obtained after surgery.

Conditions

Interventions

RADIATION

indium-111-exendin SPECT/CT

SPECT/CT imaging after injection with In-111-DTPA-exendin-4

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Martin Gotthardt, Prof. Dr. · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-16
Primary Completion
2021-06-14
Completion
2021-06-14

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03889496 on ClinicalTrials.gov